Arvee Laboratories (India) Limited submitted its financial results for the quarter and full year ended March 31, 2026, to the National Stock Exchange on May 19, 2026, following a board meeting held the same day. The filing marks the conclusion of the company's FY26 reporting cycle.
Stock Performance and Valuation
Shares of Arvee Laboratories closed at ₹166.00 on May 19, 2026, registering a gain of ₹10.60 or 6.82% on the day, suggesting the market responded positively to the board meeting outcome. The stock is currently trading at a price-to-earnings (PE) ratio of 82.52, which is exactly in line with the sector PE of 82.52, indicating the stock is valued at par with its pharmaceutical peer group at this time.
52-Week Range Context
The current price of ₹166.00 sits in the lower half of the stock's 52-week trading band. The stock touched a 52-week high of ₹290.78 on December 19, 2025, and a 52-week low of ₹129.11 on March 30, 2026. At the current level, the stock is trading approximately 42.9% below its 52-week peak and roughly 28.6% above its 52-week trough, reflecting a partial recovery from the late-March sell-off.
Trading Activity and Delivery Data
Trading volumes on the day of the announcement were relatively thin, with only 1,135 shares changing hands. However, the delivery percentage stood at 65.55%, meaning nearly two-thirds of the traded volume resulted in actual delivery rather than intraday squaring off. A delivery percentage above 50% is generally considered indicative of genuine investor interest rather than speculative activity, lending some credibility to the day's price move despite low absolute volumes.
The stock's daily volatility is recorded at 3.96%, which is notable for a small-cap pharmaceutical company with a market capitalisation of ₹182.93 crore. Investors should factor this level of price swings into their risk assessment.
Dividend History
Arvee Laboratories has no dividend history on record with the exchange. The company has not declared any dividend in the periods tracked, meaning income-seeking investors have not received any cash distribution from this stock. The absence of a dividend track record is consistent with the profile of a small-cap company that may be reinvesting earnings for growth or may have limited distributable surplus.
Company Background
Arvee Laboratories (India) Limited, identified by ISIN INE006Z01016 and NSE ticker symbol ARVEE, operates in the pharmaceutical sector. As a small-cap listed entity with a market cap of ₹182.93 crore, it falls in the lower tier of the listed pharmaceutical universe on Indian exchanges.
What This Means for Investors
- The submission of FY26 results removes near-term uncertainty around financial disclosures, though the actual numbers have not been publicly detailed in this announcement.
- The PE ratio of 82.52, matching the sector PE, suggests no premium or discount to peers based on current earnings, but this multiple warrants scrutiny given the small-cap status.
- The complete absence of dividend history means total return is entirely dependent on capital appreciation.
- Low trading volumes alongside a high delivery percentage present a mixed liquidity signal that investors should monitor closely before making any position-sizing decisions.